The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group.
Open accessAbstract
H eart attack (acute myocardial infarction or sud- den cardiac death related to disease of the large arteries supplying the heart) and isch- emic stroke (focal neurological deficit secondary to cerebrovascular disease of the large and small arteries supplying the brain or emboli from the heart or aorta) are among the foremost serious health problems in the Western hemisphere.Because coronary artery disease is so prevalent, medical treatment and coronary revas- cularization, through coronary artery bypass grafting and/or percutaneous coronary angioplasty, are impor- tant components of health care costs in the United States.The purpose of this report, which is based on a concise review of the current knowledge about the role of aspirin in cardiovascular disease, is to provide a position statement for physicians to serve as a guideline for the use of aspirin in the primary and secondary prevention of cardiovascular disease.Role of Platelets and Thrombosis in Cardiovascular Disease Platelets, platelet products, and thrombosis play a critical role in cardiovascular disease, particularly in the development and progression of coronary artery disease leading to acute coronary syndromes (i.e., heart attack), transient cerebral ischemic attack, acute cerebral infarc- tion or ischemic stroke, and in the early occlusion rates associated with coronary artery bypass grafting and percutaneous coronary angioplasty.They are also likely to be important factors in the fibroproliferative lesions that result from mechanical or immunological injury to the endothelium. Coronary Artery Disease Progression and Acute Coronary SyndromesEach year in the United States about 1.5 million people suffer heart attacks, most related to coronary thrombosis.Nearly 300,000 die before admission to the hospital, and another 200,000 die within the first month, with most of these deaths occurring during the first 24 "Aspirin As a Therapeutic Agent in Cardiovascular Disease" was approved by the American Heart Association's Board of Directors on October 23, 1992.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Effect of Dipyridamole and Aspirin on Late Vein-Graft Patency after Coronary Bypass Operations
Chesebro, J. H., Fuster, V., Elveback, L. R., Clements, I. P., Smith, H. C., Holmes, D. R., Bardsley, W. T., Pluth, J. R., Wallace, R. B., Puga, F. J., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198401263100401 · Cited by 516
Self-citation
Cited by
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
ACC/AHA guidelines for the management of patients with acute myocardial infarction
Committee Members, Ryan, T. J., Anderson, J. L., Antman, E. M., Braniff, B. A., Brooks, N. H., Califf, R. M., Hillis, L. D., Hiratzka, L. F., Rapaport, E., et al. (1996) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00392-0 · Cited by 1,850
Schmedtje, J. F., Ji, Y.-S., Liu, W.-L., DuBois, R. N., & Runge, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.601 · Cited by 668
Rogers, W. J., Canto, J. G., Lambrew, C. T., Tiefenbrunn, A. J., Kinkaid, B., Shoultz, D. A., Frederick, P. D., & Every, N. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00996-7 · Cited by 657
Kulik, A., Ruel, M., Jneid, H., Ferguson, T. B., Hiratzka, L. F., Ikonomidis, J. S., Lopez-Jimenez, F., McNallan, S. M., Patel, M., Roger, V. L., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000182 · Cited by 448
Metadata
- Authors
- Fuster, V, Dyken, M. L., Vokonas, P. S., & Hennekens, C.
- Venue
- Circulation
- Published
- 1993-02
- Volume
- 87
- Issue
- 2
- Pages
- 659-675
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1988116828
- Cited by
- 206
- References
- 2
- FWCI
- 17.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.